BridgeBio Pharma Total Current Assets 2018-2024 | BBIO
BridgeBio Pharma total current assets from 2018 to 2024. Total current assets can be defined as the sum of all assets that are classified as current because they will provide a benefit within one year.
BridgeBio Pharma Annual Total Current Assets
(Millions of US $) |
| 2023 |
$478 |
| 2022 |
$549 |
| 2021 |
$889 |
| 2020 |
$643 |
| 2019 |
$569 |
| 2018 |
$445 |
| 2017 |
$ |
BridgeBio Pharma Quarterly Total Current Assets
(Millions of US $) |
| 2024-09-30 |
$445 |
| 2024-06-30 |
$616 |
| 2024-03-31 |
$783 |
| 2023-12-31 |
$478 |
| 2023-09-30 |
$588 |
| 2023-06-30 |
$433 |
| 2023-03-31 |
$553 |
| 2022-12-31 |
$549 |
| 2022-09-30 |
$642 |
| 2022-06-30 |
$771 |
| 2022-03-31 |
$716 |
| 2021-12-31 |
$889 |
| 2021-09-30 |
$640 |
| 2021-06-30 |
$910 |
| 2021-03-31 |
$945 |
| 2020-12-31 |
$643 |
| 2020-09-30 |
$745 |
| 2020-06-30 |
$862 |
| 2020-03-31 |
$925 |
| 2019-12-31 |
$569 |
| 2019-09-30 |
$558 |
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.260B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
